Clinical Trials Logo

Clinical Trial Summary

This is a randomized, multicenter, open-label, dose-exploration and dose-expansion study to evaluate the safety, tolerability, antitumor activity, PK, pharmacodynamics, and immunogenicity of MEDI4736 in combination with tremelimumab, MEDI4736 monotherapy or tremelimumab monotherapy in participants with metastatic or recurrent gastric or gastroesophageal junction adenocarcinoma.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT02340975
Study type Interventional
Source MedImmune LLC
Contact
Status Completed
Phase Phase 1/Phase 2
Start date March 31, 2015
Completion date April 29, 2019

See also
  Status Clinical Trial Phase
Recruiting NCT04098796 - PD-1 Antibody + XELOX in 1st Line Serum A-fetoprotein (AFP)-Elevated Gastric or Gastroesophageal Junction Adenocarcinoma Phase 2
Completed NCT03849469 - A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors Phase 1
Active, not recruiting NCT03752398 - A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3) Phase 1
Recruiting NCT05994456 - Neoadjuvant Toripalimab for dMMR/MSI-H Gastric Cancer Phase 2
Recruiting NCT05482893 - PT886 For Treatment of Patients With Metastatic/Advanced Gastric, Gastroesophageal Junction and Pancreatic Adenocarcinoma (the TWINPEAK Study) Phase 1/Phase 2
Active, not recruiting NCT05941481 - Neoadjuvant Chemo-hypoRT Plus PD-1 Antibody (Tislelizumab) in Resectable LA-G/GEJ Phase 2
Completed NCT03517488 - A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors Phase 1
Completed NCT04192734 - Retrospective Study of Ramucirumab and Paclitaxel in Gastric or Gastroesophageal Junction Adenocarcinoma
Not yet recruiting NCT05218148 - SOX Combined With Sintilimab and Trastuzumab Versus SOX Regimen in the Perioperative Treatment of HER2-positive Locally Advanced Gastric Adenocarcinoma Phase 2